Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials.

BMJ Open · 2013 · PMC3612819 · PMID 23485717

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In this set of trials, docetaxel-based regimens showed a trend towards better results than vinorelbine-based regimens, but the difference was not significant for either OS (HR=0.92, p=0.089) or PFS (HR=0.97, p=0.44).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.